The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2023 | Evaluating post-infusion CAR-Treg cells to identify patients resistant to CD19 CAR-T therapy
Zinaida Good, PhD, Stanford University, Stanford, CA, discusses a study which evaluated post-infusion CAR-T regulatory (CAR-Treg) cells in patients with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel). In this study, Treg cells associated with poor prognosis and progression were identified, and Dr Good further comments on how lineage tracing may be used to identify novel biomarkers of response. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
